Literature DB >> 15972169

Incidence and outcome of complications following restorative proctocolectomy.

Katsuhiko Arai1, Kazutaka Koganei, Hideaki Kimura, Minako Akatani, Fumihiko Kitoh, Akira Sugita, Tsuneo Fukushima.   

Abstract

BACKGROUND: Complications were analyzed in 296 patients with ulcerative colitis who underwent restorative proctocolectomy.
METHODS: In 96.3% of patients, the pouch was anastomosed using the double stapling method. A total of 44.6% of patients underwent restorative proctocolectomy in 1 stage without ileostomy and 53% in 2 stages. Complications were divided into 2 stages: early (within 1 month) and late (after 1 month); moreover, the annual incidences were calculated, mean onset time, and pouch survival rate.
RESULTS: The overall incidence of complications was 52.7%. Early complications (13.2%) occurred significantly less often than late complications (46.3%) (P < .05). Thirty-five (17.7%) of 198 complications required surgery. The cumulative 5- and 10-year pouch survival rate was 99%, respectively.
CONCLUSIONS: The rate of complications after restorative proctocolectomy was almost equivalent to that in other reports, but the pouch survival rate was very high.

Entities:  

Mesh:

Year:  2005        PMID: 15972169     DOI: 10.1016/j.amjsurg.2005.05.001

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  11 in total

1.  Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Munira Essat; Paul Tappenden; Shijie Ren; Alice Bessey; Rachel Archer; Ruth Wong; Alan Lobo; Sami Hoque
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

2.  Outcomes after laparoscopic surgery in children with inflammatory bowel disease.

Authors:  Ivan R Diamond; J Ted Gerstle; Peter C W Kim; Jacob C Langer
Journal:  Surg Endosc       Date:  2010-04-16       Impact factor: 4.584

3.  Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland.

Authors:  Pawel Petryszyn; Pawel Ekk-Cierniakowski; Grzegorz Zurakowski
Journal:  Therap Adv Gastroenterol       Date:  2020-08-25       Impact factor: 4.409

4.  Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: relationship with colonic metaplasia.

Authors:  Livia Biancone; Emma Calabrese; Giampiero Palmieri; Carmelina Petruzziello; Sara Onali; Giuseppe-Sigismondo Sica; Marta Cossignani; Giovanna Condino; Kiron-Moy Das; Francesco Pallone
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

5.  A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.

Authors:  Paul Tappenden; Shijie Ren; Rachel Archer; Rebecca Harvey; Marrissa Martyn-St James; Hasan Basarir; John Stevens; Alan Lobo; Sami Hoque
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

Review 6.  Update of complications and functional outcome of the ileo-pouch anal anastomosis: overview of evidence and meta-analysis of 96 observational studies.

Authors:  Sharonne de Zeeuw; Usama Ahmed Ali; Usama Ahmed Ali; Rogier A R T Donders; Willem E Hueting; Frederik Keus; Cees J H M van Laarhoven
Journal:  Int J Colorectal Dis       Date:  2012-01-10       Impact factor: 2.571

7.  Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.

Authors:  Candace L Beilman; Nguyen Xuan Thanh; Victoria Ung; Christopher Ma; Karen Wong; Karen I Kroeker; Thomas Lee; Haili Wang; Arto Ohinmaa; Phil Jacobs; Brendan P Halloran; Richard N Fedorak
Journal:  Can J Gastroenterol Hepatol       Date:  2016-10-03

8.  Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.

Authors:  Luis Hernandez; Hiroyo Kuwabara; Anshul Shah; Kaoru Yamabe; Heather Burnett; Kyle Fahrbach; Maria Koufopoulou; Ryuichi Iwakiri
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

9.  Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.

Authors:  Ewa Stawowczyk; Paweł Kawalec; Andrzej Pilc
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

10.  Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.

Authors:  Ewa Stawowczyk; Paweł Kawalec; Andrzej Pilc
Journal:  Eur J Clin Pharmacol       Date:  2016-08-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.